Confirmatory Phase III study of Nasodine Nasal Spray (povidone-iodine 0.5%) as a symptomatic treatment for early stage common cold in the natural setting.
Virucidal pilot study of Nasodine® (povidone-iodine 0.5%) nasal spray in people in South Africa with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.
Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.
100 Clinical Results associated with Firebrick Pharma Ltd.
0 Patents (Medical) associated with Firebrick Pharma Ltd.
100 Deals associated with Firebrick Pharma Ltd.
100 Translational Medicine associated with Firebrick Pharma Ltd.